| |
|
BEFORE ARIPIPRAZOLE
(N=198) |
DURING ARIPIPRAZOLE
(N=199) |
PVALUE |
| Type of therapy |
Monotherapy |
185 (93.43%) |
185 (92.96%) |
p = 0.85 |
| Combination therapy |
13 (6.57%) |
14 (7.04%) |
| Type of AP treatment |
FGA |
33 (16.67%) |
5 (35.71%) |
NA |
| FGA-FGA |
4 (2.02%) |
0 |
| SGA |
151 (76.26%) |
9 (64.29%) |
| FGA-SGA |
6 (3.03%) |
0 |
| FGA-FGA-SGA |
1 (0.51%) |
0 |
| SGA-SGA |
2 (1.01%) |
0 |
| SGA-SGA-SGA |
1 (0.51%) |
0 |
| Duration of treatment (days) |
Mean (SD) |
1476.48 (1843.46) |
478.18 (579.73) |
p < 0.0001 |
| ARI initial dosage |
Mean (SD) |
- |
10.31 (5.15) |
NA |
| ARI final dosage |
Mean (SD) |
- |
19.67 (7.30) |
NA |
| Any AE |
No |
51 (25.76%) |
116 (58.29%) |
p < 0.0001 |
| Yes |
147 (74.24%) |
83 (41.71%) |
| AE |
Weight gain |
90 (45.45%) |
10 (5.03%) |
p < 0.0001 |
| Dizziness |
13 (6.57%) |
10 (5.03%) |
p = 0.52 |
| Appetite change |
20 (10.10%) |
10 (5.03%) |
P = 0.06 |
| Fatigue |
46 (23.23%) |
10 (5.03%) |
p < 0.0001 |
| GI Disturb |
2 (1.01%) |
7 (3.52%) |
p = 0.17 |
| Akathisia |
33 (16.67%) |
51 (25.63%) |
p = 0.03 |
| Sedation |
51 (25.76%) |
11 (5.53%) |
p < 0.0001 |
| Cognitive |
34 (17.17%) |
1 (0.50%) |
p < 0.0001 |
| Movement |
32 (16.16%) |
7 (3.52%) |
p < 0.0001 |
| White blood disorder |
1 (0.51%) |
0 |
p = 1.00 |
| Libido loss |
40 (20.20%) |
3 (1.51%) |
p < 0.0001 |
| Vision disturbance |
4 (2.02%) |
3 (1.51%) |
p = 1.00 |
| Vision changes |
0 |
0 |
p = 1.00 |
| Other |
11 (5.56%) |
15 (7.54%) |
p = 0.42 |
| Any diabetes or cardiovascular events |
No |
186 (93.94%) |
189 (94.97%) |
p = 0.66 |
| Yes |
12 (6.06%) |
10 (5.03%) |
| Diabetes or cardiovascular event |
Stroke / Transient Ischemic Attack |
0 |
0 |
NA |
| EKG changes cardiac rhythm disturbance |
1 (0.51%) |
1 (0.50%) |
NA |
| Hypertension or blood pressure change |
7 (3.54%) |
4 (2.01%) |
p = 0.36 |
| Chest pain |
0 |
1 (0.50%) |
p = 1.00 |
| Diabetes / hyperglycemia |
7 (3.54%) |
7 (3.52%) |
p = 1.00 |
